Chris Shibutani
Stock Analyst at Goldman Sachs
(3.14)
# 1,183
Out of 4,413 analysts
75
Total ratings
47.73%
Success rate
0.76%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Maintains: Neutral | $650 → $723 | $781.10 | -7.44% | 6 | Apr 11, 2024 | |
| ERAS Erasca | Maintains: Buy | $6 → $7 | $2.01 | +248.26% | 3 | Apr 2, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Neutral | $40 → $4 | $1.81 | +120.99% | 7 | Mar 11, 2024 | |
| SDGR Schrödinger | Maintains: Neutral | $29 → $26 | $24.38 | +6.64% | 1 | Mar 1, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $8 → $9 | $3.61 | +149.31% | 4 | Mar 1, 2024 | |
| BNTX BioNTech SE | Maintains: Neutral | $113 → $100 | $88.82 | +12.59% | 6 | Feb 28, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $56 → $50 | $27.70 | +80.51% | 2 | Feb 20, 2024 | |
| OGN Organon & Co. | Maintains: Neutral | $16 → $18 | $18.61 | -3.28% | 3 | Feb 20, 2024 | |
| UTHR United Therapeutics | Upgrades: Neutral | $213 → $215 | $234.33 | -8.25% | 2 | Feb 12, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $134 → $153 | $137.54 | +11.24% | 2 | Jan 25, 2024 | |
| ABBV AbbVie | Upgrades: Buy | $173 | $162.64 | +6.37% | 4 | Dec 11, 2023 | |
| NKTR Nektar Therapeutics | Upgrades: Outperform | n/a | $1.46 | - | 4 | Nov 9, 2023 | |
| MCRB Seres Therapeutics | Maintains: Sell | $4 → $1.25 | $0.99 | +26.19% | 2 | Nov 3, 2023 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $81 → $69 | $43.94 | +57.03% | 2 | Oct 30, 2023 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $30 | $21.13 | +41.98% | 2 | Oct 11, 2023 | |
| INVA Innoviva | Maintains: Neutral | $15 → $13 | $15.11 | -13.96% | 2 | Mar 3, 2023 | |
| RVMD Revolution Medicines | Maintains: Neutral | $20 → $23 | $37.28 | -38.30% | 3 | Mar 1, 2023 | |
| VTYX Ventyx Biosciences | Initiates: Buy | $50 | $3.74 | +1,236.90% | 1 | Dec 19, 2022 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $40 → $52 | $33.62 | +54.67% | 2 | Dec 16, 2022 | |
| PFE Pfizer | Upgrades: Buy | $47 → $60 | $25.62 | +134.19% | 2 | Dec 13, 2022 | |
| TRDA Entrada Therapeutics | Maintains: Neutral | $13 → $18 | $11.85 | +51.90% | 4 | Nov 8, 2022 | |
| EXAI Exscientia | Maintains: Buy | $23 → $20 | $4.95 | +304.04% | 2 | May 24, 2022 | |
| ALKS Alkermes | Initiates: Buy | $35 | $24.54 | +42.62% | 1 | Apr 20, 2022 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $163 → $181 | $144.59 | +25.18% | 2 | Apr 12, 2022 | |
| TNGX Tango Therapeutics | Initiates: Buy | n/a | $7.70 | - | 1 | Sep 7, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $3.10 | - | 1 | Jul 14, 2020 | |
| ARDX Ardelyx | Initiates: Outperform | n/a | $6.40 | - | 1 | Feb 10, 2020 | |
| PBYI Puma Biotechnology | Downgrades: Market Perform | n/a | $5.07 | - | 2 | Jan 24, 2018 | |
| RDUS Radius Health | Downgrades: Market Perform | n/a | $17.42 | - | 1 | May 2, 2017 |
Eli Lilly
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $781.10
Upside: -7.44%
Erasca
Apr 2, 2024
Maintains: Buy
Price Target: $6 → $7
Current: $2.01
Upside: +248.26%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Neutral
Price Target: $40 → $4
Current: $1.81
Upside: +120.99%
Schrödinger
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $24.38
Upside: +6.64%
Revance Therapeutics
Mar 1, 2024
Maintains: Neutral
Price Target: $8 → $9
Current: $3.61
Upside: +149.31%
BioNTech SE
Feb 28, 2024
Maintains: Neutral
Price Target: $113 → $100
Current: $88.82
Upside: +12.59%
Royalty Pharma
Feb 20, 2024
Maintains: Buy
Price Target: $56 → $50
Current: $27.70
Upside: +80.51%
Organon & Co.
Feb 20, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $18.61
Upside: -3.28%
United Therapeutics
Feb 12, 2024
Upgrades: Neutral
Price Target: $213 → $215
Current: $234.33
Upside: -8.25%
Neurocrine Biosciences
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $137.54
Upside: +11.24%
AbbVie
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $162.64
Upside: +6.37%
Nektar Therapeutics
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.46
Upside: -
Seres Therapeutics
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.99
Upside: +26.19%
Bristol-Myers Squibb Company
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $43.94
Upside: +57.03%
Syndax Pharmaceuticals
Oct 11, 2023
Initiates: Buy
Price Target: $30
Current: $21.13
Upside: +41.98%
Innoviva
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $15.11
Upside: -13.96%
Revolution Medicines
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $37.28
Upside: -38.30%
Ventyx Biosciences
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $3.74
Upside: +1,236.90%
Kymera Therapeutics
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $33.62
Upside: +54.67%
Pfizer
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.62
Upside: +134.19%
Entrada Therapeutics
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $11.85
Upside: +51.90%
Exscientia
May 24, 2022
Maintains: Buy
Price Target: $23 → $20
Current: $4.95
Upside: +304.04%
Alkermes
Apr 20, 2022
Initiates: Buy
Price Target: $35
Current: $24.54
Upside: +42.62%
Johnson & Johnson
Apr 12, 2022
Maintains: Neutral
Price Target: $163 → $181
Current: $144.59
Upside: +25.18%
Tango Therapeutics
Sep 7, 2021
Initiates: Buy
Price Target: n/a
Current: $7.70
Upside: -
Repare Therapeutics
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.10
Upside: -
Ardelyx
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $6.40
Upside: -
Puma Biotechnology
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.07
Upside: -
Radius Health
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $17.42
Upside: -